NCT04259450 is a Phase 1, PHASE2 clinical trial of 14 mg AFM24 in Advanced Solid Tumor, sponsored by Affimed GmbH.

Who is sponsoring NCT04259450?

NCT04259450 is sponsored by Affimed GmbH.

What drugs are being tested in NCT04259450?

Interventions in NCT04259450: 14 mg AFM24, 40 mg AFM24, 80 mg AFM24, 160 mg AFM24, 320 mg AFM24, 480 mg AFM24, 720 mg AFM24.

What condition does NCT04259450 study?

NCT04259450 studies Advanced Solid Tumor.

Is NCT04259450 still recruiting?

NCT04259450 is currently terminated. Last updated 17 July 2025.

Are results published for NCT04259450?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-07-17 · How we verify

NCT04259450

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess AFM24 in Advanced Solid Cancers

Terminated Phase 1, PHASE2 Results posted Last updated 17 July 2025

What this trial tests

Phase 1, PHASE2 trial testing 14 mg AFM24 in Advanced Solid Tumor in 85 participants. Terminated before completion.

Timeline

7 April 2020

Primary endpoint
12 July 2023

24 June 2024

Quick facts

Lead sponsor	Affimed GmbH
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	85
Start date	7 April 2020
Primary completion	12 July 2023
Estimated completion	24 June 2024
Sites	13 locations across United Kingdom, Germany, South Korea, United States, Spain

Drugs / interventions tested

14 mg AFM24
40 mg AFM24 — full drug profile →
80 mg AFM24 — full drug profile →
160 mg AFM24 — full drug profile →
320 mg AFM24
480 mg AFM24 — full drug profile →
720 mg AFM24 — full drug profile →

Conditions studied

Advanced Solid Tumor — all drugs for Advanced Solid Tumor →

Sponsor

Affimed GmbH — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Phase 1: The Number of Subjects With Dose Limiting Toxicities (DLTs) During Cycle 1 Primary · During Cycle 1 (up to 28 days)

The number of patients with dose limiting toxicities (DLTs) in the first cycle, as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0. DLT is defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to underlying disease, disease progression, inter-current illness, or concomitant medications, that occurs ≤28 days following the first dose of AFM24 (Cycle 1).

Group	Value	95% CI
Phase 1- 14 mg Cohort 1	0
Phase 1- 40 mg Cohort 2	1
Phase 1- 80 mg Cohort 3	0
Phase 1- 160 mg Cohort 4	0
Phase 1- 320 mg Cohort 5	0
Phase 1- 480 mg Cohort 6	0
Phase 1- 720 mg Cohort 7	0

Phase 2a: Overall Response Rate (Complete Response [CR] + Partial Response [PR]) Primary · Up to approximately 16 weeks.

Overall response as defined by achieving confirmed CR and/or PR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Partial or complete response needs to be confirmed with repeated assessment at least 4 weeks after the initial assessment.

Group	Value	95% CI
Phase 2- CRC 480 mg Cohort A	0
Phase 2- ccRCC 480 mg Cohort B	0
Phase 2- NSCLC 480 mg Cohort C	2

Phase 1: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Secondary · From the start of first infusion till the last infusion + 30 days, up to approximately 43 weeks.

Adverse Events (AEs) will be summarized with patient counts by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Classes (SOCs) and Preferred Terms (PTs).

Group	Value	95% CI
Phase 1- 14 mg Cohort 1	2
Phase 1- 40 mg Cohort 2	6
Phase 1- 80 mg Cohort 3	4
Phase 1- 160 mg Cohort 4	5
Phase 1- 320 mg Cohort 5	6
Phase 1- 480 mg Cohort 6	6
Phase 1- 720 mg Cohort 7	6

Phase 1: The Number of Subjects With Serious Adverse Events (SAEs) Secondary · From the start of first infusion till the last infusion + 30 days, up to approximately 43 weeks.

Serious adverse Events (SAEs) will be summarized with patient counts by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Classes (SOCs) and Preferred Terms (PTs).

Group	Value	95% CI
Phase 1- 14 mg Cohort 1	2
Phase 1- 40 mg Cohort 2	3
Phase 1- 80 mg Cohort 3	2
Phase 1- 160 mg Cohort 4	2
Phase 1- 320 mg Cohort 5	4
Phase 1- 480 mg Cohort 6	3
Phase 1- 720 mg Cohort 7	2

Phase 1: Area Under the Concentration-time Curve From Time 0 to Time Tau (7 Days) of AFM24 in Plasma Secondary · Pre-dose (2 hours maximum) and 15, 30, 45 min after start of infusion (SOI) and end of infusion (EOI) and 1, 4, 18, 24, 48, 144 hours after EOI on Cycle 1 Day 22.

Area under the concentration-time curve from time 0 to time tau (7 days) of AFM24 in plasma (AUC0-168)

Group	Value	95% CI
Phase 1- 14 mg Cohort 1	53400	± 61700
Phase 1- 40 mg Cohort 2	549000	± 254000
Phase 1- 80 mg Cohort 3	1290000	± 395000
Phase 1- 160 mg Cohort 4	4940000	± 1370000
Phase 1- 320 mg Cohort 5	18100000	± 6120000
Phase 1- 480 mg Cohort 6	28700000	± 7620000
Phase 1- 720 mg Cohort 7	40200000	± 12000000

Phase 1: Maximum Plasma Concentration (Cmax) of AFM24 Secondary · Pre-dose (2 hours maximum) and 15, 30, 45 min after start of infusion (SOI) and end of infusion (EOI) and 1, 4, 18, 24, 48, 144 hours after EOI on Cycle 1 Day 1 and on pre-dose (2 hours maximum) Cycle 1 Day 8.

Maximum measured concentration (Cmax) of AFM24 in plasma

Group	Value	95% CI
Phase 1- 14 mg Cohort 1	3290	± 2860
Phase 1- 40 mg Cohort 2	13200	± 3100
Phase 1- 80 mg Cohort 3	29200	± 6620
Phase 1- 160 mg Cohort 4	60900	± 17600
Phase 1- 320 mg Cohort 5	204000	± 55600
Phase 1- 480 mg Cohort 6	298000	± 71100
Phase 1- 720 mg Cohort 7	354000	± 104000

Phase 1: Time of Maximum Observed Concentration (Tmax) of AFM24 Secondary · Pre-dose (2 hours maximum) and 15, 30, 45 min after start of infusion (SOI) and end of infusion (EOI) and 1, 4, 18, 24, 48, 144 hours after EOI on Cycle 1 Day 22.

First time to maximum observed concentration of AFM24 sampled during a dosing interval.

Group	Value	95% CI
Phase 1- 14 mg Cohort 1	1.84	± 1.19
Phase 1- 40 mg Cohort 2	3.43	± 1.97
Phase 1- 80 mg Cohort 3	5.63	± 1.71
Phase 1- 160 mg Cohort 4	5.64	± 1.30
Phase 1- 320 mg Cohort 5	7.18	± 0.564
Phase 1- 480 mg Cohort 6	7.52	± 1.38
Phase 1- 720 mg Cohort 7	5.21	± 0.280

Phase 1: Minimum Plasma Concentration (Cmin) of AFM24 Secondary · Pre-dose (2 hours maximum) and 15, 30, 45 min after start of infusion (SOI) and end of infusion (EOI) and 1, 4, 18, 24, 48, 144 hours after EOI on Cycle 1 Day 1 and on pre-dose (2 hours maximum) Cycle 1 Day 22.

Minimum measured concentration (Cmin) of AFM24 in plasma

Group	Value	95% CI
Phase 1- 14 mg Cohort 1	32.7	± 46.2
Phase 1- 40 mg Cohort 2	311	± 281
Phase 1- 80 mg Cohort 3	810	± 482
Phase 1- 160 mg Cohort 4	12000	± 3540
Phase 1- 320 mg Cohort 5	73800	± 40600
Phase 1- 480 mg Cohort 6	117000	± 49600
Phase 1- 720 mg Cohort 7	233000	± 113000

Phase 1: The Number of Subjects Who Developed Anti-drug Antibodies (ADAs) and Neutralizing ADAs During Treatment With AFM24 Secondary · Pre-dose cycle 1 Day 1 and end of treatment, up to approximately 39 weeks.

The number of subjects who developed anti-drug antibodies (ADAs) at any time during the study.

Group	Value	95% CI
Phase 1- 14 mg Cohort 1	1
Phase 1- 40 mg Cohort 2	4
Phase 1- 80 mg Cohort 3	2
Phase 1- 160 mg Cohort 4	3
Phase 1- 320 mg Cohort 5	1
Phase 1- 480 mg Cohort 6	0
Phase 1- 720 mg Cohort 7	1

Phase 1: Overall Response Rate (Complete Response (CR) + Partial Response (PR)) Secondary · From the start of first infusion till the last infusion + 30 days, up to approximately 43 weeks.

Group	Value	95% CI
Phase 1- 14 mg Cohort 1	0
Phase 1- 40 mg Cohort 2	0
Phase 1- 80 mg Cohort 3	0
Phase 1- 160 mg Cohort 4	0
Phase 1- 320 mg Cohort 5	0
Phase 1- 480 mg Cohort 6	0
Phase 1- 720 mg Cohort 7	0

Phase 1: Disease Control Rate (Complete Response (CR) + Partial Response (PR) +Stable Disease (SD)) Secondary · From the start of first infusion till the last infusion + 30 days, up to approximately 43 weeks.

Disease control as defined by achieving CR and/or PR and/or SD assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Group	Value	95% CI
Phase 1- 14 mg Cohort 1	0
Phase 1- 40 mg Cohort 2	1
Phase 1- 80 mg Cohort 3	0
Phase 1- 160 mg Cohort 4	0
Phase 1- 320 mg Cohort 5	0
Phase 1- 480 mg Cohort 6	2
Phase 1- 720 mg Cohort 7	1

Phase 2a: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Secondary · From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks.

Adverse Events (AEs) will be summarized with patient counts by Medical Dictionary for Regulatory Activities (MedDRA) System Organ Classes (SOCs) and Preferred Terms (PTs).

Group	Value	95% CI
Phase 2- CRC 480 mg Cohort A	19
Phase 2- ccRCC 480 mg Cohort B	8
Phase 2- NSCLC 480 mg Cohort C	23

Adverse events — posted to ClinicalTrials.gov

Time frame: From the start of first infusion till the last infusion + 30 days, up to approximately 105 weeks. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Phase 1- 14 mg Cohort 1

Serious: 2/2 (100%)

Deaths: 1/2

Phase 1- 40 mg Cohort 2

Serious: 3/6 (50%)

Deaths: 6/6

Phase 1- 80 mg Cohort 3

Serious: 2/4 (50%)

Deaths: 4/4

Phase 1- 160 mg Cohort 4

Serious: 2/5 (40%)

Deaths: 3/5

Phase 1- 320 mg Cohort 5

Serious: 4/6 (67%)

Deaths: 4/6

Phase 1- 480 mg Cohort 6

Serious: 3/6 (50%)

Deaths: 4/6

Phase 1- 720 mg Cohort 7

Serious: 2/6 (33%)

Deaths: 6/6

Phase 2- CRC 480 mg Cohort A

Serious: 8/19 (42%)

Deaths: 14/19

Phase 2- ccRCC 480 mg Cohort B

Serious: 6/8 (75%)

Deaths: 6/8

Phase 2- NSCLC 480 mg Cohort C

Serious: 8/23 (35%)

Deaths: 7/23

Serious adverse events (46 terms)

Reaction	System	Phase 1- 14 mg Cohort 1	Phase 1- 40 mg Cohort 2	Phase 1- 80 mg Cohort 3	Phase 1- 160 mg Cohort 4	Phase 1- 320 mg Cohort 5	Phase 1- 480 mg Cohort 6	Phase 1- 720 mg Cohort 7	Phase 2- CRC 480 mg Cohort A	Phase 2- ccRCC 480 mg Coho…	Phase 2- NSCLC 480 mg Coho…
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Infusion related reaction	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—
Myocardial infarction	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Sinus tachycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—	—	—	—	—
Pain	General disorders	—	—	—	—	—	—	—	—	—	—
Cholangitis	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Cholangitis infective	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Hip fracture	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—
Failure to thrive	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—
Metastatic neoplasm	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—
Haematuria	Renal and urinary disorders	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—
Hypoxia	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—
Pleural effusion	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—
Productive cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—
Tachypnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—
Blindness	Eye disorders	—	—	—	—	—	—	—	—	—	—
Gastrointestinal haemorrhage	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—

Other adverse events (155 terms — click to expand)

Reaction	System	Phase 1- 14 mg Cohort 1	Phase 1- 40 mg Cohort 2	Phase 1- 80 mg Cohort 3	Phase 1- 160 mg Cohort 4	Phase 1- 320 mg Cohort 5	Phase 1- 480 mg Cohort 6	Phase 1- 720 mg Cohort 7	Phase 2- CRC 480 mg Cohort A	Phase 2- ccRCC 480 mg Coho…	Phase 2- NSCLC 480 mg Coho…
Infusion related reaction	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—
Neutrophil count decreased	Investigations	—	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—
Dermatitis acneiform	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—
Blood bilirubin increased	Investigations	—	—	—	—	—	—	—	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Abdominal discomfort	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—	—	—
Lymphopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Proctalgia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—
Pleural effusion	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—	—	—	—	—
Vision blurred	Eye disorders	—	—	—	—	—	—	—	—	—	—
Tachycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Cytokine release syndrome	Immune system disorders	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Abdominal pain, Infusion related reaction, Myocardial infarction, Sinus tachycardia, Small intestinal obstruction, Fatigue, Non-cardiac chest pain, Pain.

Data from ClinicalTrials.gov NCT04259450 adverse events section.

Sponsor's own description

AFM24-101 is a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies. AFM24 is a tetravalent bispecific (anti-human EGFR x anti-human CD16A) innate immune cell engaging recombinant antibody being developed to target EGFR-expressing solid tumors and has been designed to specifically utilize the cytotoxic potential of the innate immune system, in particular natural killer cells and macrophages for the specific and efficient elimination of EGFR expressing cancer cells.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging new therapeutic antibody derivatives for cancer treatment.
Jin S, Sun Y, Liang X, Gu X, et al · · 2022 · cited 304× · PMID 35132063 · DOI 10.1038/s41392-021-00868-x
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.
Maskalenko NA, Zhigarev D, Campbell KS. · · 2022 · cited 174× · PMID 35314852 · DOI 10.1038/s41573-022-00413-7
Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J, Yang Y, Wang G, Liu M. · · 2022 · cited 127× · PMID 36389699 · DOI 10.3389/fimmu.2022.1035276
Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
Shim H. · · 2020 · cited 95× · PMID 32111076 · DOI 10.3390/biom10030360
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements.
Sun Y, Yu X, Wang X, Yuan K, et al · · 2023 · cited 62× · PMID 37719370 · DOI 10.1016/j.apsb.2023.05.023
Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.
Capuano C, Pighi C, Battella S, De Federicis D, et al · · 2021 · cited 62× · PMID 34065399 · DOI 10.3390/cancers13102500
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
Wingert S, Reusch U, Knackmuss S, Kluge M, et al · · 2021 · cited 55× · PMID 34325617 · DOI 10.1080/19420862.2021.1950264
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Yin N, Li X, Zhang X, Xue S, et al · · 2024 · cited 48× · PMID 38773064 · DOI 10.1038/s41392-024-01826-z

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumor

Currently open trials in the same condition.

NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting

Other Affimed GmbH trials

Trials by the same sponsor.

NCT05883449 — Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL · Phase 2 · terminated
NCT05817058 — First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia · Phase 1 · terminated
NCT05109442 — Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers · Phase 1, PHASE2 · terminated
NCT04101331 — Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04259450 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Affimed GmbH
Last refreshed: 17 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04259450.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing